Agents DT56a – an ideal phytoSERM for treatment of estrogen deficit
Authors:
Tomáš Fait
Authors‘ workplace:
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
Published in:
Prakt Gyn 2016; 20(2): 74-76
Category:
Gynecology and Obstetrics
Overview
Extract DT56a is made from fermented soya´s beans. It contents standardized mixture of fytoestrogenes. It works as ideal selective estrogen receptor modulator (SERM) in praeclinical and clinical tests. DT56a in daily dose 644 mg has equal efficacy for acute climacteric syndrom (hot flashes, night sweats, sexual wellbeing) as hormone replacement therapy. It has possitive influence on vaginal mucouse and osteoblast´s function. It improves bone mineral density also in hyperglycaemic situation. At the same time DT56a has neutral or antiestrogenic (in case of estrogene presence) influence on breast tissue and uterine tissue, no influence on level of estrogene, gonadoliberines, thyroid hormones, lipid metabolism, liver function and blood coagulability.
Key words:
DT56a – climacteric syndrome – menopause – SERM
Sources
1. Somjen D, Katzburg S, Lieberherr M et al. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In-Vitro. J Steroid Biochemistry Molecular Biology 2006; 98(1): 90–96.
2. Somjen D, Katzburg S, Sharon O et al. DT56a (Femarelle), contrary to estradiol-17β, is effective in human derived female osteoblasts in hyperglycemic condition. J Steroid Biochem Mol Biol 2011; 123(1–2): 25–29.
3. Yoles I, Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. Eur J Obstet Gynecol Reprod Biol 2006, 130(1): 140–141.
4. Somjen D, Yoles I. DT56a stimulans creatine kinase specific aktivity in vascular tissues of rats. J Endocrinol Invest 2003; 26(10): 966–971.
5. Pluchino NP, Merlini S, Cubeddu A et al. Brain-region responsiveness to DT56a (Femarelle) administration allopregnanolone and opioid content in ovariectomized rats. Menopause 2009; 16(5): 1037–1043.
6. Somjen D, Katzburg S, Livne E et al. DT56a (Femarelle) Stimulates Bone Formation in Female Rats. BJOG 2005; 112(7): 981–985.
7. Somjen D, Yoles I. DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J Steroid Biochem Mol Biol 2003; 86(1): 93–98.
8. Somjen D, Katzburg S, Kohen F et al. The effects of native and synthetic estrogenic compounds as well as vitamin D less-calcemic analogs on adipocytes content in rat bone marrow. J Endocrinol Invest 2011; 34(2): 106–110.
9. Oropeza MV, Orozco S, Ponce H et al. Tofupill lack peripheral estrogen-like actions in the rat reproductive tract. Reprod Toxicol 2005; 20(2): 261–266.
10. Labos G, Trakakis E, Pliatsika P et al. Efficacy and safety of DT56a compared to hormone therapy in Greek postmenopausal women. J Endocrinol Invest 2013; 36(7): 521–526.
11. Sánchez-Borrego R, Mendoza N, Llaneza P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms. Climacteric 2015; 18(6): 813–816.
12. Yoles I, Yogev Y, Frenkel Y et al. Tofupill/Femarelle (DT56a) – a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 2003; 10(6): 522–525.
13. Yoles I, Yogev Y, Frenkel Y et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (DT56a) for the Treatment of Menopausal Symptoms. Clin Exp Obstet Gynecol 2004; 31(2): 123–126.
14. Nachtigall MJ, Jessel RH, Flaumenhaft R et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011; 18(3): 285–288.
15. Nachtigall M, Naftolin F, Nachtigall R et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. In: Menopause book of abstract of the NAMS 22nd Annual Meeting Sept 2011.
16. Sánchez-Borrego R, Navarro MC, Llaneza P et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy. Climacteric 2015; 18(3): 350–357.
17. Somjen D, Katzburg S, Knoll E et al. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). J Steroid Biochem Mol Biol 2007; 104(3–5): 252–258.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2016 Issue 2
Most read in this issue
- Selected orthopaedic indications for caesarean section
- Agents DT56a – an ideal phytoSERM for treatment of estrogen deficit
- Women’s experience of abortion
- Local infiltration analgesia during caesarean delivery in general anesthesia